查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1798083

化膿性汗腺炎市場預測（至 2032 年）：按臨床分期、皮膚狀況、治療類型、給藥途徑、分銷管道、最終用戶和地區進行的全球分析

Hidradenitis Suppurativa Market Forecasts to 2032 - Global Analysis By Clinical Stage (Hurley Stage 1, Hurley Stage 2 and Hurley Stage 3), Skin Condition, Treatment Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球化膿性汗腺炎市場預計在 2025 年達到 8.5306 億美元，到 2032 年將達到 13.4316 億美元，預測期內的複合年成長率為 6.7%。

化膿性汗腺炎 (HS) 是一種慢性發炎性皮膚病，其特徵是出現疼痛性結節、膿瘍和竇道（竇道），通常發生在皮膚相互摩擦的部位，例如鼠蹊部、臀部和乳房下方。由於發炎和毛囊堵塞，該疾病經常復發，嚴重影響生活品質，並留下疤痕和不適。 HS 的確切病因尚不清楚，但可能的原因包括遺傳、荷爾蒙變化、免疫系統異常、肥胖和吸煙。根據病情嚴重程度，可能需要長期治療，包括改變生活方式、藥物治療和手術。此病在早期常被誤診。

根據印度的臨床研究，全球盛行率為0.00033%至4.1%之間，且HS與高血壓、肥胖、高血脂症、胰島素抗性、METABOLIC INC.症候群、卵巢症候群（PCOS）等代謝紊亂有關。

提高疾病意識和盛行率

化膿性汗腺炎 (HS) 的發生率在全球範圍內穩步上升，影響著數百萬人，尤其是女性以及肥胖、METABOLIC INC.症候群或家族病史的人。歷史上，HS 診斷不足，但由於近年來的宣傳宣傳活動、患者權益團體和教育舉措，該疾病已得到患者和醫療保健專業人員的廣泛認可。這提高了診斷率，鼓勵了早期就診，並減少了病恥感。臨床知識的累積也促進了嚴重程度分類的改進，這有助於選擇最合適的治療策略。隨著越來越多的人獲得早期診斷和治療，對有效治療的需求將不斷成長，從而推動市場擴張。

生技藥品治療成本高昂

生技藥品治療的高昂成本是HS市場面臨的最大障礙之一。雖然這些療法比傳統療法更有效，但其高昂的成本往往限制了其廣泛應用，尤其是在中低收入族群。Adalimumab、Secukinumab單抗和比美珠單抗等生技藥品的年均費用高達數千美元，給患者和醫療保健系統都帶來了巨大的壓力。雖然新興市場擁有保險覆蓋和報銷體系，但藥物的可及性仍然不平等且有限。高昂的費用使許多患者無法開始治療，甚至導致他們完全停止治療。

標靶治療和生技藥品的成長

生技藥品和標靶治療的持續進展代表著HS最大的市場機會之一。儘管Humira、Cosentyx和Vimzerex等現有生技藥品已經徹底改變了治療方式，但下一代生技藥品、JAK抑制劑和口服小分子化合物正處於研發階段，這些化合物具有更高的療效和更便捷的潛力。這些創新藥物旨在解決尚未滿足的需求，例如抗治療性、注射疲勞和療效反應率的差異性。日益激烈的競爭以及現有生技藥品在HS治療中的應用擴展，也可能降低成本並改善藥物的可及性。如果企業成功推出更安全、更有效、更獨特的治療方法，就能佔據相當大的市場。

專利到期，競爭激烈

HS 治療市場競爭日益激烈，市場上已有許多標靶治療和生技藥品，還有更多正在研發中。這種競爭雖然增加了治療選擇，但也危及現有療法的市場佔有率和定價權。當關鍵生技藥品（例如 Humira）的專利到期時，它們為開發生物相似藥開闢了可能性，這可能會降低老字型大小企業的利潤。激烈的競爭也可能導致激進的定價策略，從而降低行業利潤率。此外，如果公司無法透過更好的給藥系統、更高的安全性或獨特的作用機制來實現產品的差異化，那麼在這個快速變化的治療市場中，就有可能落後。

COVID-19的影響

新冠疫情對化膿性汗腺炎 (HS) 市場產生了多重影響。大範圍的封鎖和醫療體系的中斷最初導致診斷延遲、皮膚科醫生就診次數減少以及正在進行的治療中斷，尤其是對於需要去醫院或診所就診生技藥品的患者而言。許多臨床試驗的暫停也減緩了新治療方法的開發。同時，疫情加速了數位健康平台和遠端醫療的普及，增強了後續護理和遠距患者管理。此外，人們對慢性病管理的認知不斷提高以及對強大醫療保健系統的需求，導致近期 HS 研發資金激增。

預計腫脹樣病變部分將是預測期內最大的

預計在預測期內，癤狀病變領域將佔據最大的市場佔有率。這些病灶通常表現為疼痛腫脹的腫塊，類似臀部、鼠蹊部或腋窩反覆出現的癤子。這些病變經常破裂、流膿並引起劇烈疼痛，導致許多患者就醫。癤狀病變是診斷、治療和研究的主要焦點，因此，它們在 HS 各個階段的高發病率佔據了市場主導地位。因此，治療這些病變是大多數治療方法和臨床研究的首要重點。

預計皮膚科診所部門在預測期內的複合年成長率最高

預計皮膚科專科診所細分市場將在預測期內達到最高成長率。對先進專業治療的需求日益成長是這一成長的主要驅動力，因為HS通常需要標靶治療、生技藥品和外科手術，而這些治療最好由皮膚科醫生處理。患者更青睞這些診所，因為他們能夠全面處理複雜病例，並獲得尖端治療方案，並能準確診斷。此外，疾病認知度的提高、持續的臨床試驗以及精通慢性皮膚病的皮膚科醫生的存在，也促進了該市場的發展。隨著醫療保健系統越來越重視專科門診護理，HS治療的應用也越來越集中在皮膚科診所。

佔比最高的地區

預計北美地區將在預測期內佔據最大的市場佔有率，這得益於 HS 的高盛行率、患者和醫療保健專業人員對 HS 的高度認知，以及生技藥品等尖端治療方案的廣泛可用性。該地區完善的醫療保健基礎設施、優惠的報銷政策以及創新治療方法的早期核准，為患者提供廣泛的治療機會。領先製藥公司的存在和正在進行的臨床試驗進一步加強了治療創新和應用。此外，廣泛的患者權益倡導和支持系統有助於長期疾病管理和早期診斷，鞏固了北美在全球 HS 市場的主導地位。

複合年成長率最高的地區

預計亞太地區將在預測期內呈現最高的複合年成長率，這得益於尖端皮膚病護理服務日益普及、醫療保健支出不斷成長以及人們對該疾病的認知不斷提高。由於肥胖、荷爾蒙失調和文明病的普遍存在，中國、印度和日本等國家的 HS 發病率也在上升。政府和私人公司正在建設醫療保健基礎設施，而製藥公司則透過合作夥伴關係、分級定價和患者支援計劃擴大其業務範圍。此外，數位健康平台和遠端醫療的快速普及也擴大了專家諮詢的管道。這些因素共同使亞太地區成為 HS 治療成長率最高的地區。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場參與企業進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 透過產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球化膿性汗腺炎市場（依臨床階段）

  • 介紹
  • 哈雷第一階段
  • 哈雷2級
  • 哈雷3級

6. 全球化膿性汗腺炎市場（依皮膚狀況）

  • 介紹
  • 毛囊炎
  • 腫脹樣病變
  • 深部結節
  • 痤瘡樣病變
  • 其他

7. 全球化膿性汗腺炎市場（依治療類型）

  • 介紹
  • 藥理
    • 抗生素
    • 生技藥品
    • 荷爾蒙療法
    • 皮質類固醇
  • 治療
    • 手術切除
    • 雷射治療
    • 動態療法（PDT）
    • 切開引流
  • 其他治療類型

8. 全球化膿性汗腺炎市場（依給藥途徑）

  • 介紹
  • 口服
  • 腸外（注射）
  • 局部的
  • 其他

9. 全球化膿性汗腺炎市場（依通路）

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 專業經銷商
  • 其他

第 10 章全球化膿性汗腺炎市場（依最終用戶）

  • 介紹
  • 醫院
  • 專科皮膚科診所
  • 居家照護
  • 其他

第 11 章全球化膿性汗腺炎市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc
  • Johnson & Johnson Private Limited
  • MoonLake Immunotherapeutics Inc
  • Boehringer Ingelheim Inc
  • Sanofi
  • UCB Biopharma
  • Kymera Therapeutics
  • Priovant Therapeutics
  • UNION Therapeutics
  • Incyte Corporation
  • CSL Behring
Product Code: SMRC30453

According to Stratistics MRC, the Global Hidradenitis Suppurativa Market is accounted for $853.06 million in 2025 and is expected to reach $1343.16 million by 2032 growing at a CAGR of 6.7% during the forecast period. Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition characterized by the development of painful nodules, abscesses, and tunnels (sinus tracts) typically occurring in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. Hair follicle inflammation and blockage cause the disease to flare up frequently, which can have a major negative influence on quality of life and leave scars and discomfort behind. Although the precise cause of HS is unknown, potential causes include genetics, hormonal changes, immune system dysregulation, obesity, and smoking. Depending on its severity, it may necessitate long-term management that includes lifestyle changes, medication, or surgery. It is frequently misdiagnosed in its early stages.

According to Indian clinical research, worldwide prevalence ranges from 0.00033% to 4.1%, and HS is associated with metabolic derangements-like hypertension, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, and polycystic ovarian syndrome (PCOS).

Market Dynamics:

Driver:

Growing illness awareness and prevalence

The prevalence of Hidradenitis Suppurativa (HS) is steadily increasing worldwide, affecting millions, particularly women and individuals with obesity, metabolic syndrome, or a family history of the condition. Although historically under diagnosed, the disease is now more widely recognized by patients and medical professionals owing to recent awareness campaigns, patient advocacy groups, and educational initiatives. This has improved diagnostic rates, promoted earlier consultations, and lessened stigma. Improved disease severity classification brought about by growing clinical knowledge also helps choose the best course of treatment. As more people receive early diagnosis and treatment, there will likely be a greater need for efficient treatments, which will drive market expansion.

Restraint:

Expensive cost of biologic treatments

The high expense of biologic therapies is one of the biggest barriers to the HS market. Although these treatments are more effective than traditional methods, their cost frequently prevents them from being widely available, particularly in areas with low and middle incomes. Adalimumab, secukinumab, and bimekizumab are examples of biologics that can cost thousands of dollars per patient each year, putting a strain on both individuals and healthcare systems. Even though developed markets have insurance coverage and reimbursement programs, access is still unequal and limited. The exorbitant expenses prevent many patients from starting treatment or from stopping it altogether, which prevent the best possible adoption and general market growth.

Opportunity:

Growth of targeted and biologic treatments

The ongoing advancement of biologics and targeted therapies represents one of the largest market opportunities in HS. Treatment has already been revolutionized by current biologics like Humira, Cosentyx, and Bimzelx; however, next-generation biologics, JAK inhibitors, and oral small molecules with potentially higher efficacy and convenience are also in the therapeutic pipeline. Unmet needs like treatment resistance, injection fatigue, and variable response rates are what these innovative agents seek to address. Increased competition and the expansion of indications for currently available biologics into HS may also lower costs and improve access. Businesses have the potential to gain a sizable portion of the market if they can successfully launch safer, more effective, and unique treatments.

Threat:

Patent expiration and fierce competition

The market for HS therapeutics is getting more and more competitive, with numerous targeted therapies and biologics already on the market and numerous others in development. This competition increases treatment options, but it also puts current medications' market share and pricing power at risk. Leading biologics' patent expirations, like those of Humira, allow for the development of biosimilars, which may lower profits for well-established companies. Intense rivalry may also lead to aggressive pricing tactics, which would reduce industry profit margins. Moreover, businesses that don't differentiate their products with better delivery systems, enhanced safety, or distinctive mechanisms of action run the risk of falling behind in this rapidly changing therapeutic market.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Hidradenitis Suppurativa (HS) market. Widespread lockdowns and disruptions to the healthcare system initially caused delays in diagnosis, fewer consultations with dermatologists, and disruptions in ongoing treatment, especially for patients who needed to visit a hospital or clinic for biologics. The development of new treatments was also slowed by the suspension of numerous clinical trials. On the other hand, the pandemic hastened the adoption of digital health platforms and telemedicine, which enhanced follow-up care and remote patient management. Additionally, there has been a recent surge in funding for HS research and treatment development due to increased awareness of managing chronic diseases and the need for robust healthcare systems.

The boil-like lesions segment is expected to be the largest during the forecast period

The boil-like lesions segment is expected to account for the largest market share during the forecast period. The most prevalent and clinically significant form of the disease are these lesions, which frequently manifest as painful, swollen lumps that resemble recurring boils in places like the buttocks, groin, and armpits. They frequently burst, release pus, and cause excruciating pain, which prompts many patients to seek medical help. Since boil-like lesions are the main focus of diagnosis, treatment, and research, their high prevalence throughout all stages of HS accounts for their market dominance. As a result, managing this segment is a major focus of the majority of therapeutic approaches and clinical trials.

The specialty dermatology clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty dermatology clinics segment is predicted to witness the highest growth rate. The rising need for sophisticated and specialized care is the main driver of this growth, since HS frequently necessitates targeted treatments, biologics, and surgical procedures that are best handled by dermatology specialists. These clinics are preferred by patients due to their thorough handling of complex cases, access to cutting-edge treatments, and accurate diagnosis. Additionally, this market is strengthened by growing awareness of the illness, ongoing clinical trials, and the availability of dermatologists with expertise in chronic skin conditions. The adoption of HS treatments is increasingly concentrated in dermatology clinics as healthcare systems place an emphasis on specialized outpatient care.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the disease's high prevalence, patients' and healthcare professionals' strong awareness of it, and the broad availability of cutting-edge treatment options like biologics. Broad patient access is supported by the region's well-established healthcare infrastructure, advantageous reimbursement practices, and early regulatory approvals of innovative therapies. Treatment innovation and adoption are further bolstered by the presence of top pharmaceutical companies and ongoing clinical trials. Furthermore, expanding patient advocacy initiatives and support systems has helped with long-term disease management and early diagnosis, solidifying North America's leading position in the global HS market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, increased access to cutting-edge dermatology care, increased healthcare spending, and growing disease awareness. In nations like China, India, and Japan, the incidence of HS is also rising due to the prevalence of obesity, hormonal imbalances, and lifestyle-related illnesses. Infrastructure is being upgraded by governments and private healthcare providers, and pharmaceutical companies are growing their footprints through collaborations, tiered pricing, and patient support initiatives. Additionally, the quick uptake of digital health platforms and telemedicine is opening up access to expert consultations. Together, these elements make Asia-Pacific the region with the fastest rate of growth for HS treatments.

Key players in the market

Some of the key players in Hidradenitis Suppurativa Market include AbbVie Inc., Novartis AG, Eli Lilly and Company, Pfizer Inc., Amgen Inc, Johnson & Johnson Private Limited, MoonLake Immunotherapeutics Inc, Boehringer Ingelheim Inc, Sanofi, UCB Biopharma, Kymera Therapeutics, Priovant Therapeutics, UNION Therapeutics, Incyte Corporation and CSL Behring.

Key Developments:

In May 2025, Eli Lilly and Company and Purdue University announced a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline.

In February 2025, AbbVie and Xilio Therapeutics, Inc. announced collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated biologics.

In February 2025, Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront payment of $925m. The transaction includes $2.15bn of potential additional payments, contingent on regulatory and sales milestones.

Clinical Stages Covered:

  • Hurley Stage 1
  • Hurley Stage 2
  • Hurley Stage 3

Skin Conditions Covered:

  • Folliculitis
  • Boil-like Lesions
  • Deep Nodules
  • Acneiform Lesions
  • Other Skin Conditions

Treatment Types Covered:

  • Pharmacological
  • Procedural
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral (Injectables)
  • Topical
  • Other Route of Administration

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Distributors
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Specialty Dermatology Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hidradenitis Suppurativa Market, By Clinical Stage

  • 5.1 Introduction
  • 5.2 Hurley Stage 1
  • 5.3 Hurley Stage 2
  • 5.4 Hurley Stage 3

6 Global Hidradenitis Suppurativa Market, By Skin Condition

  • 6.1 Introduction
  • 6.2 Folliculitis
  • 6.3 Boil-like Lesions
  • 6.4 Deep Nodules
  • 6.5 Acneiform Lesions
  • 6.6 Other Skin Conditions

7 Global Hidradenitis Suppurativa Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Pharmacological
    • 7.2.1 Antibiotics
    • 7.2.2 Biologics
    • 7.2.3 Hormonal Therapy
    • 7.2.4 Corticosteroids
  • 7.3 Procedural
    • 7.3.1 Surgical Excision
    • 7.3.2 Laser Therapy
    • 7.3.3 Photodynamic Therapy (PDT)
    • 7.3.4 Incision and Drainage
  • 7.4 Other Treatment Types

8 Global Hidradenitis Suppurativa Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parenteral (Injectables)
  • 8.4 Topical
  • 8.5 Other Route of Administration

9 Global Hidradenitis Suppurativa Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Specialty Distributors
  • 9.6 Other Distribution Channels

10 Global Hidradenitis Suppurativa Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Dermatology Clinics
  • 10.4 Homecare Settings
  • 10.5 Other End Users

11 Global Hidradenitis Suppurativa Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AbbVie Inc.
  • 13.2 Novartis AG
  • 13.3 Eli Lilly and Company
  • 13.4 Pfizer Inc.
  • 13.5 Amgen Inc
  • 13.6 Johnson & Johnson Private Limited
  • 13.7 MoonLake Immunotherapeutics Inc
  • 13.8 Boehringer Ingelheim Inc
  • 13.9 Sanofi
  • 13.10 UCB Biopharma
  • 13.11 Kymera Therapeutics
  • 13.12 Priovant Therapeutics
  • 13.13 UNION Therapeutics
  • 13.14 Incyte Corporation
  • 13.15 CSL Behring

List of Tables

  • Table 1 Global Hidradenitis Suppurativa Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Hidradenitis Suppurativa Market Outlook, By Clinical Stage (2024-2032) ($MN)
  • Table 3 Global Hidradenitis Suppurativa Market Outlook, By Hurley Stage 1 (2024-2032) ($MN)
  • Table 4 Global Hidradenitis Suppurativa Market Outlook, By Hurley Stage 2 (2024-2032) ($MN)
  • Table 5 Global Hidradenitis Suppurativa Market Outlook, By Hurley Stage 3 (2024-2032) ($MN)
  • Table 6 Global Hidradenitis Suppurativa Market Outlook, By Skin Condition (2024-2032) ($MN)
  • Table 7 Global Hidradenitis Suppurativa Market Outlook, By Folliculitis (2024-2032) ($MN)
  • Table 8 Global Hidradenitis Suppurativa Market Outlook, By Boil-like Lesions (2024-2032) ($MN)
  • Table 9 Global Hidradenitis Suppurativa Market Outlook, By Deep Nodules (2024-2032) ($MN)
  • Table 10 Global Hidradenitis Suppurativa Market Outlook, By Acneiform Lesions (2024-2032) ($MN)
  • Table 11 Global Hidradenitis Suppurativa Market Outlook, By Other Skin Conditions (2024-2032) ($MN)
  • Table 12 Global Hidradenitis Suppurativa Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 13 Global Hidradenitis Suppurativa Market Outlook, By Pharmacological (2024-2032) ($MN)
  • Table 14 Global Hidradenitis Suppurativa Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 15 Global Hidradenitis Suppurativa Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 16 Global Hidradenitis Suppurativa Market Outlook, By Hormonal Therapy (2024-2032) ($MN)
  • Table 17 Global Hidradenitis Suppurativa Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 18 Global Hidradenitis Suppurativa Market Outlook, By Procedural (2024-2032) ($MN)
  • Table 19 Global Hidradenitis Suppurativa Market Outlook, By Surgical Excision (2024-2032) ($MN)
  • Table 20 Global Hidradenitis Suppurativa Market Outlook, By Laser Therapy (2024-2032) ($MN)
  • Table 21 Global Hidradenitis Suppurativa Market Outlook, By Photodynamic Therapy (PDT) (2024-2032) ($MN)
  • Table 22 Global Hidradenitis Suppurativa Market Outlook, By Incision and Drainage (2024-2032) ($MN)
  • Table 23 Global Hidradenitis Suppurativa Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 24 Global Hidradenitis Suppurativa Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 25 Global Hidradenitis Suppurativa Market Outlook, By Oral (2024-2032) ($MN)
  • Table 26 Global Hidradenitis Suppurativa Market Outlook, By Parenteral (Injectables) (2024-2032) ($MN)
  • Table 27 Global Hidradenitis Suppurativa Market Outlook, By Topical (2024-2032) ($MN)
  • Table 28 Global Hidradenitis Suppurativa Market Outlook, By Other Route of Administration (2024-2032) ($MN)
  • Table 29 Global Hidradenitis Suppurativa Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 30 Global Hidradenitis Suppurativa Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 31 Global Hidradenitis Suppurativa Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 32 Global Hidradenitis Suppurativa Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 33 Global Hidradenitis Suppurativa Market Outlook, By Specialty Distributors (2024-2032) ($MN)
  • Table 34 Global Hidradenitis Suppurativa Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 35 Global Hidradenitis Suppurativa Market Outlook, By End User (2024-2032) ($MN)
  • Table 36 Global Hidradenitis Suppurativa Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 37 Global Hidradenitis Suppurativa Market Outlook, By Specialty Dermatology Clinics (2024-2032) ($MN)
  • Table 38 Global Hidradenitis Suppurativa Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 39 Global Hidradenitis Suppurativa Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.